UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Tenofovir-associated renal and bone toxicity

Woodward, CLN; Hall, AM; Williams, IG; Madge, S; Copas, A; Nair, D; Edwards, SG; ... Connolly, JO; + view all (2009) Tenofovir-associated renal and bone toxicity. HIV MED , 10 (8) 482 - 487. 10.1111/j.1468-1293.2009.00716.x.

Full text not available from this repository.

Abstract

ObjectivesThe aims of the study were to describe the clinical presentation and renal and bone abnormalities in a case series of HIV-infected patients receiving treatment with tenofovir (TDF), and to recommend appropriate screening for toxicity related to TDF.MethodsPatients were identified from referrals to a specialist HIV renal clinic. Patients were included if treatment with TDF was assessed as the primary cause of the renal function impairment and clinical data were available prior to and following discontinuation of TDF treatment. Data were collected from case note review and clinic databases.ResultsTwenty-two patients (1.6% of all those who received TDF) were identified with TDF-associated renal toxicity. All had normal serum creatinine prior to TDF therapy. All presented with proteinuria. On stopping TDF, renal function improved. Eight patients had confirmed Fanconi syndrome. Twelve patients presented with bone pain and osteomalacia was confirmed on an isotope bone scan in seven of these patients. The findings (in those patients tested) of tubular proteinuria, reduced tubular transport maximum of phosphate (TmP), and glycosuria were all consistent with the proximal tubule being the site of toxicity.ConclusionRenal toxicity remains a concern in patients treated with TDF. Clinical presentation may be with renal dysfunction, Fanconi syndrome or osteomalacia. Our investigations suggest proximal tubular toxicity as a common pathogenic mechanism.

Type: Article
Title: Tenofovir-associated renal and bone toxicity
DOI: 10.1111/j.1468-1293.2009.00716.x
Keywords: highly active antiretroviral therapy, osteomalacia, renal disease, tenofovir, toxicity, ANTIRETROVIRAL THERAPY, DISOPROXIL FUMARATE, NAIVE PATIENTS, URINE PROTEIN, SAFETY, DYSFUNCTION, INHIBITORS, FAILURE, RATIO, TERM
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Institute for Global Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Institute for Global Health > Infection and Population Health
URI: http://discovery.ucl.ac.uk/id/eprint/130812
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item